SFI
TCRT icon

Susquehanna Fundamental Investments’s Alaunos Therapeutics TCRT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-146
Closed -$58K – 1888
2021
Q2 		$58K Buy
+146
New +$68.2K ﹤0.01% 1616

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna Fundamental Investments's TCRT Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Alaunos Therapeutics (TCRT) in Q3 2021, closing a stake of 146 shares — an estimated $58K sold.

Susquehanna Fundamental Investments first reported a position in TCRT in Q2 2021 and held it in 1 quarter. The position peaked at $58K in Q2 2021. 162 funds tracked by Wall St. Rank hold TCRT as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Alaunos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 146 Alaunos Therapeutics shares in Q3 2021, an estimated $58K.
  • Susquehanna Fundamental Investments first reported a position in Alaunos Therapeutics in Q2 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Alaunos Therapeutics position peaked at $58K in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.